ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

REVATIO INJECTION
Pulmonary hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

REVATIO INJECTION Rx

Generic Name and Formulations:
Sildenafil 10mg/vial; soln for IV inj.

Company:
Pfizer Inc.



Therapeutic Use:

RECENT UPDATES

09/23/14
Added Limitation of use.

Indications for REVATIO INJECTION:

Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in patients who are temporarily unable to take oral Revatio. Limitation of use: no beneficial effect on exercise capacity in adding sildenafil to bosentan therapy.

Adult Dose for REVATIO INJECTION:

Give by IV bolus inj 2.5mg or 10mg three times daily.

Children's Dose for REVATIO INJECTION:

Not recommended.

See Also:

REVATIO

REVATIO ORAL SUSPENSION

Pharmacological Class:

Phosphodiesterase type 5 inhibitor (cGMP-specific).

Contraindications:

Concomitant organic nitrates.

Warnings/Precautions:

Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia. Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP<90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions:

See Contraindications. Hypotension with nitrates. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Potentiated by inhibitors of CY3A4 or CYP2C9. Antagonized by CYP3A4 inducers. Concomitant α-blockers (eg, doxazosin) or amlodipine may cause symptomatic hypotension (monitor BP). Potentiates bleeding risk with Vit. K antagonists. Concomitant Viagra or other PDE5 inhibitors: not recommended.

Adverse Reactions:

Epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea worsened, rhinitis, sinusitis, myalgia, pyrexia, paresthesia; hypotension, vision or hearing loss, priapism, vaso-occlusive crisis.

Metabolism:

Hepatic (CYP3A, CYP2C9).

Elimination:

Fecal (primary), renal.

Generic Availability:

Tabs (YES); Susp, inj (NO)

How Supplied:

Tabs—90; Susp—112mL (w. bottle adapter, oral syringe); Single-use vial—1

Sign Up for Free e-newsletters